Document:

4

                 PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT

                  THIS PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT (the
"Agreement") is entered into as of _______, 2007, by and among BIOSTAR
PHARMACEUTICALS, INC., a Maryland corporation (the "Company"), with headquarters
located at 76 Cranbrook Road, Cockeysville, County of Baltimore, MD 21020, and
the purchasers (collectively, the "Purchasers" and each a "Purchaser") set forth
on SCHEDULE 1 hereof, with regard to the following:

                                    RECITALS

                  A. The Company and the Purchasers are executing and delivering
this Agreement in reliance upon the exemption from securities registration
afforded by the provisions of Regulation D ("Regulation D") and/or Regulation S,
as promulgated by the United States Securities and Exchange Commission (the
"SEC") under the Securities Act of 1933, as amended (the "Securities Act").

                  B. The Purchasers desire to (a) purchase, upon the terms and
conditions stated in this Agreement, shares of the Company's Series A
Convertible Preferred Stock, $.001 par value per share (the "Preferred Stock")
and (b) purchase, upon the terms and conditions stated in this Agreement, the
Common Stock Purchase Warrants (the "Warrants") to purchase shares of the
Company's Common Stock, $.001 par value per share ("Common Stock"), in the form
attached hereto as EXHIBIT A. The shares of Common Stock issuable upon exercise
of or otherwise pursuant to the Warrants are referred to herein as "Warrant
Shares." The Preferred Stock, the Warrants and the Warrant Shares are
collectively referred to herein as the "Securities". The Warrants and any other
documents or agreements executed in connection with the transactions
contemplated hereunder, are hereinafter referred to as the "Transaction
Documents."

                                   AGREEMENTS

                  NOW, THEREFORE, in consideration of their respective promises
contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and the Purchasers
hereby agree as follows:

                                   ARTICLE I

                PURCHASE AND SALE OF PREFERRED STOCK AND WARRANTS

1.1 Purchase of Preferred Stock and Warrants. Subject to the terms and
conditions of this Agreement, the issuance, sale and purchase of the Preferred
Stock and Warrants shall be consummated in a "Closing." The purchase price (the
"Purchase Price") shall be TEN DOLLARS ($10.00) per Unit, for a Unit consisting
of one share of Preferred Stock and one Warrant to purchase such number of
shares of Common Stock as shall be equal to the number of shares of Common Stock
that one share of Preferred Stock shall have been converted into pursuant to a

                                       1
<PAGE>

mandatory conversion of Preferred Stock into Common Stock made at the option of
the Company pursuant to Section 3(d) of Article SIXTH of the Certificate of
Incorporation of the Company, as amended and in effect as of the date of the
Closing. _______Units shall be sold pursuant to this Agreement. On the date of
the Closing, subject to the satisfaction or waiver of the conditions set forth
in ARTICLES VI and VII hereof, the Company shall issue and sell to each
Purchaser, and each Purchaser severally agrees to purchase from the Company, the
number of Units set forth on SCHEDULE 1 hereto. Each Purchaser's obligation to
purchase Units hereunder is distinct and separate from each other Purchaser's
obligation to purchase, and no Purchaser shall be required to purchase hereunder
more than the number of Units set forth on SCHEDULE 1 hereto. The obligations of
the Company with respect to each Purchaser shall be separate from the
obligations of each other Purchaser and shall not be conditioned as to any
Purchaser upon the performance of obligations of any other Purchaser. .

         1.2 Closing Date. Subject to the satisfaction (or waiver) of the
conditions set forth in ARTICLES VI and VII below, the date and time of the
issuance, sale and purchase of the Preferred Stock and Warrants pursuant to this
Agreement shall be at 10:00 a.m. New York time, on __________, 2007.

                                   ARTICLE II
                         PURCHASER'S REPRESENTATIONS AND
                                   WARRANTIES

                  Each Purchaser represents and warrants to the Company, as of
the date hereof and as of the Closing, severally and not jointly with respect to
itself and its purchase hereunder and not with respect to any other Purchaser or
the purchase hereunder by any other Purchaser that the following statements are
true and correct:

         2.1 Investment Purpose. Purchaser is purchasing the Preferred Stock and
the Warrants for Purchaser's own account for investment only and not with a view
toward or in connection with the public sale or distribution thereof. Purchaser
will not, directly or indirectly, offer, sell, pledge or otherwise transfer its
Preferred Stock, Warrants or any interest therein except pursuant to
transactions that are exempt from the registration requirements of the
Securities Act and/or sales registered under the Securities Act. Purchaser
understands that Purchaser must bear the economic risk of this investment
indefinitely, unless the Securities are registered pursuant to the Securities
Act and any applicable state securities laws or an exemption from such
registration is available, and that the Company has no present intention of
registering any such Securities other than as contemplated by the terms of the
Company's Articles of Incorporation setting forth the designation, rights and
preferences of the Preferred Stock (the "Charter") and the terms of the Warrants
set forth in the certificate evidencing the Warrants (the "Warrant
Certificate").

         2.2 Accredited Investor/"Non-U.S." Person Status. Purchaser is an
"accredited investor" as that term is defined in Rule 501(a) of Regulation D as
provided in Exhibit B hereto or Purchaser is a "non-U.S." Person as defined
under Rule 902 of Regulation S.

         2.3 Reliance on Exemptions. Purchaser understands that the Preferred
Stock and Warrants are being offered and sold to Purchaser in reliance upon
specific exemptions from the registration requirements of United States federal

                                       2
<PAGE>

and state securities laws and that the Company is relying upon the truth and
accuracy of, and Purchaser's compliance with, the representations, warranties,
agreements, acknowledgments and understandings of Purchaser set forth herein in
order to determine the availability of such exemptions and the eligibility of
Purchaser to acquire the Common Shares and Warrants.

         2.4 Information. Purchaser has been afforded the opportunity to ask
questions of the Company, was permitted to meet with the Company's officers and
has received what the Purchaser believes to be complete and satisfactory answers
to any such inquiries. Except for the answers received by Purchaser as a result
of inquiries made by Purchaser to Company officers, and except as otherwise
provided in this Agreement, the Purchaser is not relying upon any information,
representations or warranties of any other party. Neither such inquiries nor any
other due diligence investigation conducted by Purchaser or any of its
representations shall modify, amend or affect Purchaser's right to rely on the
Company's representations and warranties contained in ARTICLE III. Purchaser
understands that Purchaser's investment in the Securities involves a high degree
of risk.

         2.5 Governmental Review. Purchaser understands that no United States
federal or state agency or any other government or governmental agency has
passed upon or made any recommendation or endorsement of the Securities.

         2.6 Transfer or Resale. Purchaser understands that (i) except as
provided in the Charter and the Warrant Certificate, the Securities have not
been and are not being registered under the Securities Act or any state
securities laws, and may not be offered, sold, pledged or otherwise transferred
unless subsequently registered thereunder or an exemption from such registration
is available (which exemption the Company expressly agrees may be established as
contemplated in clauses (b) and (c) of Section 5.1 hereof); (ii) any sale of
such Securities made in reliance on Rule 144 under the Securities Act (or a
successor rule) ("Rule 144") may be made only in accordance with the terms of
Rule 144 and further, if Rule 144 is not applicable, any resale of such
Securities without registration under the Securities Act under circumstances in
which the seller may be deemed to be an underwriter (as that term is defined in
the Securities Act) may require compliance with some other exemption under the
Securities Act or the rules and regulations of the SEC thereunder in order for
such resale to be allowed, and (iii) the Company is under no obligation to
register such Securities under the Securities Act or any state securities laws
or to comply with the terms and conditions of any exemption thereunder (in each
case, other than pursuant to the Charter and the Warrant Certificate).

         2.7 No Directed Selling Efforts. Neither Purchaser, nor any of his
affiliates, nor any person acting on its behalf or any behalf of any such
affiliate, has engaged or will engage in any activity undertaken for the purpose
of, or that reasonably could be expected to have the effect of, conditioning the
markets in the United States for the Units or Common Stock, including but not
limited to effecting any sale or short sale of the Company's securities through
Purchaser or any of his affiliates prior to the expiration of any restricted
period contained in Regulation S (any such activity being defined herein as a
"Directed Selling Effort"). To the best knowledge of the undersigned, this
Agreement and the transactions contemplated herein are not part of a plan or

                                       3
<PAGE>

scheme to evade the registration provisions of the 1933 Act, and the Units are
being purchased for investment purposes by Purchaser. Purchaser agrees that all
offers and sales of the Common Stock from the date hereof and through the
expiration of the any restricted period set forth in Rule 903 of Regulation S
(as the same may be amended from time to time hereafter) shall not be made to
U.S. Persons or for the account or benefit of U.S. Persons and shall otherwise
be made in compliance with the provisions of Regulation S and any other
applicable provisions of the Securities Act. Purchaser and its representatives
have not conducted any Directed Selling Effort as that term is used and defined
in Rule 902 of Regulation S and will not engage in any such Directed Selling
Effort within the United States through the expiration of any restricted period
set forth in Rule 903 of Regulation S.

         2.8 Legends. Purchaser understands that, subject to ARTICLE V hereof,
the certificate for the Preferred Stock and the Warrant Certificate and, until
such time as the Warrant Shares and shares of Common Stock issuable upon
conversion of the Preferred Stock (the "Conversion Shares") have been registered
under the Securities Act or otherwise may be sold by Purchaser pursuant to Rule
144 (subject to and in accordance with the procedures specified in ARTICLE V
hereof), the certificates for the Conversion Shares and the Warrant Shares will
bear a restrictive legend (the "Legend"), which will include language in
substantially the following form:

                  THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
                  REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
                  THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE
                  SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED OR SOLD OR
                  OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE
                  REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE
                  SECURITIES LAWS OR UNLESS OFFERED, SOLD OR TRANSFERRED
                  PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION
                  REQUIREMENTS OF THOSE LAWS.

         2.9 Authorization; Enforcement. This Agreement has been duly and
validly authorized, executed and delivered on behalf of Purchaser and is a valid
and binding agreement of Purchaser enforceable in accordance with its terms,
except to the extent that such validity or enforceability may be subject to or
affected by any bankruptcy, insolvency, reorganization, moratorium, liquidation
or similar laws relating to, or affecting generally the enforcement of,
creditors' rights or remedies of creditors, or by other equitable principles of
general application.

         2.10 Residency. Purchaser is a resident of the jurisdiction set forth
under Purchaser's name on the signature page hereto executed by Purchaser.

         2.11 Hedging Transactions. Purchaser does not have an existing short
position with respect to the Company's Common Stock.

                                       4
<PAGE>

                                  ARTICLE III
                  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

                  The Company represents and warrants to each Purchaser as of
the date hereof and as of the Closing that the following statements are true and
correct, except as set forth on the disclosure schedules, if any, attached
hereto as SCHEDULE 2 (the "Company Disclosure Schedules").

                  Organization and Qualification. Each of the Company and its
subsidiaries is a corporation duly organized and existing in good standing under
the laws of the jurisdiction in which it is incorporated, and has the requisite
corporate power to own its properties and to carry on its business as now being
conducted. The Company and each of its subsidiaries is duly qualified as a
foreign corporation to do business and is in good standing in every jurisdiction
where the failure so to qualify or be in good standing could reasonably be
expected to have a Material Adverse Effect. "Material Adverse Effect" means any
effect which, individually or in the aggregate with all other effects,
reasonably would be expected to be materially adverse to the business,
operations, properties, financial condition, operating results or prospects of
the Company and its subsidiaries, taken as a whole on a consolidated basis or on
the transactions contemplated hereby.

         3.1 Authorization; Enforcement. (a) The Company has the requisite
corporate power and authority to enter into and perform under the Transaction
Documents, and to issue, sell and perform its obligations with respect to the
Securities in accordance with the terms hereof and thereof and in accordance
with the terms and conditions of the Securities; (b) the execution, delivery and
performance of the Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby (including, without
limitation, the issuance of the Preferred Stock, Conversion Shares and the
Warrants and Warrant Shares, and the reservation for issuance of the Warrant
Shares) have been duly authorized by all necessary corporate action and no
further consent or authorization of the Company, its board of directors, or its
stockholders or any other Person is required with respect to any of the
transactions contemplated hereby or thereby; (c) this Agreement, the Preferred
Stock, and the Warrants have been duly executed and delivered by the Company;
and (d) this Agreement, the Preferred Stock, and the Warrants constitute legal,
valid and binding obligations of the Company enforceable against the Company in
accordance with their respective terms, except (i) to the extent that such
validity or enforceability may be subject to or affected by any bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to,
or affecting generally the enforcement of, creditors' rights or remedies of
creditors generally, or by other equitable principles of general application,
and (ii) as rights to indemnity and contribution may be limited by federal or
state securities laws. "Person" means any individual, sole proprietorship,
partnership, limited liability company, joint venture, trust, unincorporated
association, corporation, entity or government (whether federal, state, county,
city or otherwise, including, without limitation, any instrumentality, division,
agency or department thereof).

         3.2 Capitalization. There are currently 110,000,000 shares of
authorized capital stock with 100,000,000 shares of Common Stock authorized and
10 million shares of preferred stock authorized. There are currently ________
shares of Common Stock outstanding and ________ shares of preferred stock
outstanding. All of such outstanding shares of capital stock have been, or upon
issuance will be, validly issued, fully paid and nonassessable. No shares of
capital stock of the Company (including the Preferred Stock, the Conversion
Shares and the Warrant Shares) are subject to preemptive rights or any other
similar rights of the stockholders of the Company or any liens or encumbrances.
Except as disclosed in SCHEDULE 3 hereof, as of the date of this Agreement, (i)
there are no outstanding options, warrants, scrip, rights to subscribe for,

                                       5
<PAGE>

calls or commitments of any character whatsoever relating to, or securities or
rights convertible into or exercisable or exchangeable for, any shares of
capital stock of the Company or any of its subsidiaries, or contracts,
commitments, understandings or arrangements by which the Company or any of its
subsidiaries is or may become bound to issue additional shares of capital stock
of the Company or any of its subsidiaries, (ii) issuance of the Securities will
not trigger anti-dilution rights for any other outstanding or authorized
securities of the Company, (iii) up until the date of effectiveness of a
registration statement registering the re-sale of the Securities, there will be
no more than 20 million shares of common stock outstanding on a fully diluted
basis, and (iv) there are no agreements or arrangements under which the Company
or any of its subsidiaries is obligated to register the sale of any of its or
their securities under the Securities Act (except for the provisions sets forth
in the Charter and the Warrant Certificate). The Company has made available to
Purchaser true and correct copies of the Company's Articles of Incorporation as
in effect on the date hereof ("Articles of Incorporation"), and the Company's
By-laws as in effect on the date hereof (the "By-laws"). The Company has set
forth on SCHEDULE 3 hereof all instruments and agreements (other than the
Articles of Incorporation and By-laws) governing securities convertible into or
exercisable or exchangeable for Common Stock of the Company (and the Company
shall provide to Purchaser copies thereof upon the request of Purchaser).

         3.3 No Conflicts. The execution, delivery and performance of the
Transaction Documents by the Company, and the consummation by the Company of
transactions contemplated hereby and thereby (including, without limitation, the
issuance and reservation for issuance, as applicable, of the Securities) do not
and will not (a) result in a violation of the Articles of Incorporation or
By-laws or (b) conflict with, or constitute a default (or an event which, with
notice or lapse of time or both, would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture or instrument to which the Company or any of its
subsidiaries is a party, or result in a violation of any law, rule, regulation,
order, judgment or decree (including U.S. federal and state securities laws)
applicable to the Company or any of its subsidiaries, or by which any property
or asset of the Company or any of its subsidiaries, is bound or affected (except
for such possible conflicts, defaults, terminations, amendments, accelerations,
cancellations and violations as would not, individually or in the aggregate,
have a Material Adverse Effect). Neither the Company nor any of its subsidiaries
is in violation of its Articles of Incorporation or other organizational
documents. Neither the Company nor any of its subsidiaries, is in default (and
no event has occurred which has not been waived which, with notice or lapse of
time or both, could reasonably be expected to put the Company or any of its
subsidiaries in default) under, nor has there occurred any event giving others
(with notice or lapse of time or both) any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which
the Company or any of its subsidiaries is a party, except for possible
violations, defaults or rights as would not, individually or in the aggregate,
have a Material Adverse Effect. The businesses of the Company and its
subsidiaries are not being conducted, and shall not be conducted so long as a
Purchaser owns any of the Securities, in violation of any law, ordinance or
regulation of any governmental entity, except for possible violations the
sanctions for which either individually or in the aggregate would not have a
Material Adverse Effect. Except as (A) such as may be required under the
Securities Act in connection with the performance of the Company's obligations
under the Charter and Warrant Certificate, (B) filing of a Form D with the SEC,
and (C) compliance with the state securities or Blue Sky laws of applicable
jurisdictions, the Company is not required to obtain any consent, authorization
or order of, or make any filing or registration with, any court or governmental
agency or any regulatory or self-regulatory agency in order for it to execute,
deliver or perform any of its obligations under this Agreement or to perform its
obligations in accordance with the terms hereof or thereof.

                                       6
<PAGE>

         3.4 Consents. The execution, delivery and performance by the Company of
the Transaction Documents and the offer, issuance and sale of the Securities
require no consent of, action by or in respect of, or filing with, any Person,
governmental body, agency, or official other than (i) filings that have been
made pursuant to applicable state securities laws, (ii) post-sale filings
pursuant to applicable state and federal securities laws, and (iii) any consent,
action or filing that either individually or in the aggregate would not have a
Material Adverse Effect. Subject to the accuracy of the representations and
warranties of each Purchaser set forth in ARTICLE II hereof, the Company has
taken all action necessary to exempt (i) the issuance and sale of the Preferred
Stock, (ii) the issuance of the Conversion Shares, (iii) the issuance of the
Warrants, and (iv) the issuance of the Warrant Shares, from the provisions of
any stockholder rights plan or other "poison pill" arrangement, any
anti-takeover, business combination or control share law or statute binding on
the Company or to which the Company or any of its assets and properties may be
subject and any provision of the Company's Articles of Incorporation or By-laws
that is or could reasonably be expected to become applicable to the Purchasers
as a result of the transactions contemplated hereby, including without
limitation, the issuance of the Securities and the ownership, disposition or
voting of the Securities by the Purchasers or the exercise of any right granted
to the Purchaser pursuant to this Agreement or the other Transaction Documents.

         3.5 Absence of Litigation. There is no action, suit, proceeding,
inquiry or investigation before or by any court, public board, government
agency, or self-regulatory organization or body pending or, to the Company's
knowledge or any of its subsidiaries, threatened against or affecting the
Company, any of its subsidiaries, or any of their respective directors or
officers in their capacities as such. There are no facts known to the Company
which, if known by a potential claimant or governmental authority, could
reasonably be expected to give rise to a claim or proceeding which, if asserted
or conducted with results unfavorable to the Company or any of its subsidiaries,
could reasonably be expected to have a Material Adverse Effect.

         3.6 Disclosure. No information relating to or concerning the Company
set forth in this Agreement contains an untrue statement of a material fact. The
Company has not omitted to state a material fact necessary in order to make the
statements made herein or therein, in light of the circumstances under which
they were made, not misleading. Except for the execution and performance of this
Agreement, no material fact (within the meaning of the federal securities laws
of the United States and of applicable state securities laws) exists with
respect to the Company which has not been publicly disclosed.

         3.7 No General Solicitation. Neither the Company nor any distributor
participating on the Company's behalf in the transactions contemplated hereby
(if any) nor any person acting for the Company, or any such distributor, has
conducted any "general solicitation," as described in Rule 502(c) under
Regulation D, with respect to any of the Securities being offered hereby.

                                       7
<PAGE>

         3.8 No Integrated Offering. Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales of any security or solicited any offers to
buy any security under circumstances that would prevent the parties hereto from
consummating the transactions contemplated hereby pursuant to an exemption from
the registration under the Securities Act pursuant to the provisions of
Regulation D. The transactions contemplated hereby are exempt from the
registration requirements of the Securities Act, assuming the accuracy of the
representations and warranties herein contained of each Purchaser.

         3.9 No Brokers. The Company has taken no action which would give rise
to any claim by any person for brokerage commissions, finder's fees or similar
payments by Purchaser relating to this Agreement or the transactions
contemplated hereby.

                                   ARTICLE IV
                                    COVENANTS

         4.1 Reasonable Efforts. The parties shall use their commercially
reasonable efforts to timely satisfy each of the conditions described in
ARTICLES VI and VII of this Agreement and to seek its Board of Directors'
approval of this Agreement.

         4.2 Securities Laws; Disclosure; Press Release. The Company agrees to
file a Form D with respect to the Securities with the SEC as required under
Regulation D. The Company shall, on or prior to the date of Closing, take such
action as is necessary to sell the Securities to each Purchaser under applicable
securities laws of the states of the United States.

         4.3 Reservation of Common Stock. The Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number
of shares of Common Stock for the purpose of enabling the Company to issue the
Conversion Shares and the Warrant Shares.

         4.4 Corporate Existence. So long as any Purchaser beneficially owns any
Securities, the Company shall maintain its corporate existence, except in the
event of a merger, consolidation or sale of all or substantially all of the
Company's assets, as long as the surviving or successor entity in such
transaction assumes the Company's obligations hereunder and under the agreements
and instruments entered into in connection herewith.

         4.5 Hedging Transactions. No Purchaser has an existing short position
with respect to the Company's Common Stock. Each Purchaser agrees not to,
directly or indirectly, enter into any short sales with respect to the Common
Stock prior to the date on which such Purchaser is entitled to sell, transfer
the number of shares of Common Stock as to which such Purchaser proposes to
establish a short position.

         4.6 Conversion.

                 (i) Each share of Series A Stock shall automatically be
converted into shares of Common Stock at the Conversion Price (as such term
hereinafter defined) for such share, determined as hereafter provided,
immediately upon the closing of the corporation's sale of its Common Stock in an
offering pursuant to a registration statement under the Securities Act of 1933,
as amended (a "Qualified IPO"). The date of such closing is hereinafter referred
to as the "Automatic Conversion Date". In connection with a Qualified IPO, prior
to the initial filing of a registration statement related to the Qualified IPO,
the corporation shall obtain from a person, firm or entity engaged in the

                                       8
<PAGE>

business of providing evaluations or appraisals of the value of securities of
companies which is selected in good faith by the Board of Directors of the
corporation and is independent of the corporation (the "Valuation Firm") a
valuation of the Common Stock on a per share basis (the "Valuation Price") For
purposes hereof, the term "Conversion Price" shall mean the price equal to the
product obtained by multiplying (x) 1/3, times (y) 80% of the Valuation Price.
The number of shares of Common Stock issuable upon conversion of one share of
Series A Preferred shall be the quotient obtained by dividing (A) $10 by (B) the
Conversion Price. No fractional shares of Common Stock may be issued upon the
conversion of any share or shares of the Series A Preferred Stock into Common
Stock, and the number of shares of Common Stock to be issued shall be rounded up
to the nearest whole share. The Conversion Price shall be appropriately adjusted
in the event of a reorganization, recapitalization, stock split, stock dividend,
combination of shares, or similar change in the corporation's Common Stock.
Except as set forth herein, neither the corporation nor any holder of Series A
Preferred shall have the right to convert, or require the conversion of, Series
A Preferred into Common Stock or any other security or property of the
corporation or any other person.

              (ii) Mechanics of Conversion. No later than five business days
after the Automatic Conversion Date, the corporation shall deliver or cause to
be delivered a notice to each holder of the Series A Preferred (A) stating that
the Series A Preferred has been converted; (B) setting forth the number of full
shares of Common Stock to be issued due to such conversion as determined in
accordance with this Section (3)(d); (C) informing the holder of the address of
the Company or agent to which the holder may deliver its Series A Preferred
certificate in exchange for a Common Stock certificate representing the number
of shares into which such holder's Series A Preferred has been converted. Such
conversion shall be deemed to have been made upon the surrender of the
certificate for the shares of Series A Preferred to be converted, and the person
entitled to receive the shares of Common Stock issuable upon such conversion
shall be treated for all purposes as the record holder of such shares of Common
Stock at and after such time.

                                   ARTICLE V
           LEGEND REMOVAL, TRANSFER, CERTAIN SALES, ADDITIONAL SHARES

         5.1 Removal of Legend. The Legend shall be removed and the Company
shall issue a certificate without such Legend to the holder of any Security upon
which it is stamped, and a certificate for a security shall be originally issued
without the Legend, if, (a) the sale of such Security is registered under the
Securities Act, (b) such holder provides the Company with an opinion of counsel,
in form, substance and scope customary for opinions of counsel in comparable
transactions and reasonably satisfactory to the Company and its counsel (the
reasonable cost of which shall be borne by the Company if, after one (1) year,
neither an effective registration statement under the Securities Act or Rule 144
is available in connection with such sale) to the effect that a public sale or
transfer of such Security may be made without registration under the Securities
Act pursuant to an exemption from such registration requirements or (c) such
Security can be sold pursuant to Rule 144 and the holder provides the Company
with reasonable assurances that the Security can be so sold without restriction

                                       9
<PAGE>

or (d) such Security can be sold pursuant to Rule 144(k). The Company may not
make any notation on its records or give instructions to any transfer agent of
the Company that enlarge the restrictions on transfer set forth in this Section.
Each Purchaser agrees to sell all Securities, including those represented by a
certificate(s) from which the Legend has been removed, or which were originally
issued without the Legend, pursuant to an effective registration statement, in
accordance with the manner of distribution described in such registration
statement and to deliver a prospectus in connection with such sale, or in
compliance with an exemption from the registration requirements of the
Securities Act. In the event the Legend is removed from any Security or any
Security is issued without the Legend and the Security is to be disposed of
other than pursuant to the registration statement or pursuant to Rule 144, then
prior to, and as a condition to, such disposition such Security shall be
relegended as provided herein in connection with any disposition if the
subsequent transfer thereof would be restricted under the Securities Act. Also,
in the event the Legend is removed from any Security or any Security is issued
without the Legend and thereafter the effectiveness of a registration statement
covering the resale of such Security is suspended or the Company determines that
a supplement or amendment thereto is required by applicable securities laws,
then upon reasonable advance notice to Purchaser holding such Security, the
Company may require that the Legend be placed on any such Security that cannot
then be sold pursuant to an effective registration statement or Rule 144 or with
respect to which the opinion referred to in clause (b) next above has not been
rendered, which Legend shall be removed when such Security may be sold pursuant
to an effective registration statement or Rule 144 or such holder provides the
opinion with respect thereto described in clause (b) next above.

         5.2 Transfer Agent Instructions. The Company agrees that following the
effective date of the registration statement or at such time as such legend is
no longer required under Section 5.1, it will, no later than ten (10) days
following the delivery by a Purchaser to the Company or the Company's transfer
agent of a certificate representing Warrant Shares issued with a restrictive
legend (such date, the "Legend Removal Date"), deliver or cause to be delivered
to such Purchaser a certificate representing such Securities that is free from
all restrictive and other legends, registered in the name of each Purchaser or
its nominee for the Warrant Shares in such amounts determined in accordance with
the terms of the Warrants. The Company covenants that no instruction other than
such instructions referred to in this ARTICLE V, and stop transfer instructions
to give effect to Section 2.6 hereof in the case of the Warrant Shares prior to
registration of the Warrant Shares under the Securities Act, will be given by
the Company to its transfer agent and that the Securities shall otherwise be
freely transferable on the books and records of the Company. Nothing in this
Section shall affect in any way each Purchaser's obligations and agreement set
forth in Section 5.1 hereof to resell the Securities pursuant to an effective
registration statement and to deliver a prospectus in connection with such sale
or in compliance with an exemption from the registration requirements of
applicable securities laws. If (a) a Purchaser provides the Company with an
opinion of counsel, which opinion of counsel shall be in form, substance and
scope customary for opinions of counsel in comparable transactions and
reasonably satisfactory to the Company and its counsel (the reasonable cost of
which shall be borne by the Company if, after one (1) year, neither an effective
registration statement under the Securities Act or Rule 144 is available in

                                       10
<PAGE>

connection with such sale), to the effect that the Securities to be sold or
transferred may be sold or transferred pursuant to an exemption from
registration or (b) a Purchaser transfers Securities to an affiliate which is an
accredited investor (within the meaning of Regulation D under the Securities
Act) and which delivers to the Company in written form the same representations,
warranties and covenants made by Purchaser hereunder or pursuant to Rule 144,
the Company shall permit the transfer, and, in the case of the Warrant Shares,
promptly instruct its transfer agent to issue one or more certificates in such
name and in such denomination as specified by such Purchaser. The Company
acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to a Purchaser by vitiating the intent and purpose of the
transaction contemplated hereby. Accordingly, the Company acknowledges that the
remedy at law for a breach of its obligations under this ARTICLE V will be
inadequate and agrees, in the event of a breach or threatened breach by the
Company of the provisions of this ARTICLE V, that a Purchaser shall be entitled,
in addition to all other available remedies to an injunction restraining any
breach and requiring immediate issuance and transfer, without the necessity of
showing economic loss and without any bond or other security being required.

                                   ARTICLE VI
                 CONDITIONS TO THE COMPANY'S OBLIGATION TO SELL

         6.1 Conditions to the Company's Obligation to Sell. The obligation of
the Company hereunder to issue and sell the Preferred Stock and Warrants to a
Purchaser at the Closing is subject to the satisfaction, as of the date of the
Closing and with respect to such Purchaser, of each of the following conditions
thereto, provided that these conditions are for the Company's sole benefit and
may be waived by the Company at any time in its sole discretion:

                  (i) Such Purchaser shall have executed and delivered the
         signature page to this Agreement;

                  (ii) Such Purchaser shall have wired its aggregate Purchase
         Price set forth on Schedule 1 hereto to the Company;

                  (iii) The representations and warranties of such Purchaser
         shall be true and correct as of the date when made and as of the
         Closing with the same force and effect as though such representations
         and warranties had been made on and as of the date of Closing (except
         for representations and warranties that speak as of a specific date),
         and such Purchaser shall have performed, satisfied and complied in all
         material respects with the covenants, agreements and conditions
         required by this Agreement to be performed, satisfied or complied with
         by the applicable Purchaser at or prior to the Closing;

                  (iv) No statute, rule, regulation, executive order, decree,
         ruling or injunction shall have been enacted, entered, promulgated or
         endorsed by any court or governmental authority of competent
         jurisdiction or any self-regulatory organization having authority over
         the matters contemplated hereby which restricts or prohibits the
         consummation of any of the transactions contemplated by this Agreement;
         and

                  (v) The Company shall have obtained all waivers,
         authorizations, approvals and consents needed to consummate the
         transaction contemplated by this Agreement which the Company agrees to
         diligently procure.

                                       11
<PAGE>

                                  ARTICLE VII
              CONDITIONS TO EACH PURCHASER'S OBLIGATION TO PURCHASE

         7.1 The obligation of each Purchaser hereunder to purchase the
Preferred Stock and Warrants to be purchased by it on the date of the Closing is
subject to the satisfaction of each of the following conditions, provided that
these conditions are for each Purchaser's sole benefit and may be waived by such
Purchaser at any time in such Purchaser's sole discretion:

                  (i) The Company shall have executed and delivered the
         signature page to this Agreement;

                  (ii) The Company shall have delivered to the Purchaser duly
         issued certificates for the Preferred Stock and Warrants being so
         purchased by Purchaser at the Closing;

                  (iii) The representations and warranties of the Company shall
         be true and correct in all material respects as of the date when made
         and as of the Closing with the same force and effect as though such
         representations and warranties had been made on and as of the date of
         Closing, and the Company shall have performed, satisfied and complied
         in all material respects with the covenants, agreements and conditions
         required by this Agreement to be performed, satisfied or complied with
         by the Company at or prior to the Closing; and

                  (iv) No statute, rule, regulation, executive order, decree,
         ruling or injunction shall have been enacted, entered, promulgated or
         endorsed by any court or governmental authority of competent
         jurisdiction or any self-regulatory organization having authority over
         the matters contemplated hereby which prohibits the consummation of any
         of the transactions contemplated by this Agreement.

                                  ARTICLE VIII
                          GOVERNING LAW; MISCELLANEOUS

         8.1 Governing Law: Jurisdiction. This Agreement shall be governed by
and construed in accordance with the Maryland General Corporation Law (in
respect of matters of corporation law) and the laws of the State of New York (in
respect of all other matters) applicable to contracts made and to be performed
in the State of New York. The parties hereto irrevocably consent to the
jurisdiction of the United States federal courts and state courts located in the
County of New York in the State of New York in any suit or proceeding based on
or arising under this Agreement or the transactions contemplated hereby and
irrevocably agree that all claims in respect of such suit or proceeding may be
determined in such courts. The Company and each Purchaser irrevocably waives the
defense of an inconvenient forum to the maintenance of such suit or proceeding
in such forum. The Company and each Purchaser further agrees that service of
process upon the Company or such Purchaser, as applicable, mailed by the first
class mail in accordance with Section 8.6 shall be deemed in every respect
effective service of process upon the Company or such Purchaser in any suit or
proceeding arising hereunder. Nothing herein shall affect Purchaser's right to
serve process in any other manner permitted by law. The parties hereto agree
that a final non-appealable judgment in any such suit or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on such judgment
or in any other lawful manner. The parties hereto irrevocably waive any right to
a trial by jury under applicable law.

                                       12
<PAGE>

         8.2 Counterparts. This Agreement may be executed in two or more
counterparts, including, without limitation, by facsimile transmission, all of
which counterparts shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered
to the other party. In the event any signature page is delivered by facsimile
transmission, the party using such means of delivery shall cause additional
original executed signature pages to be delivered to the other parties as soon
as practicable thereafter.

         8.3 Headings. The headings of this Agreement are for convenience of
reference and shall not form part of, or affect the interpretation of, this
Agreement.

         8.4 Severability. If any provision of this Agreement shall be invalid
or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement or
the validity or enforceability of this Agreement in any other jurisdiction.

         8.5 Entire Agreement; Amendments. This Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect
to the maters covered herein and therein and, except as specifically set forth
herein or therein, neither the Company nor any Purchaser makes any
representation, warranty, covenant or undertaking with respect to such matters.
No provision of this Agreement may be waived other than by an instrument in
writing signed by the party to be charged with enforcement and no provision of
this Agreement may be amended other than by an instrument in writing signed by
the Company and each Purchaser.

         8.6 Notice. Any notice herein required or permitted to be given shall
be in writing and may be personally served or delivered by nationally-recognized
overnight courier or by facsimile machine confirmed telecopy, and shall be
deemed delivered at the time and date of receipt (which shall include telephone
line facsimile transmission). The addresses for such communications shall be:

IF TO THE COMPANY:
Biostar Pharmaceuticals, Inc.
[Address]
ATTENTION:
FACSIMILE:

         IF TO THE PURCHASERS:

                  [TO BE SUPPLIED]

Each party shall provide notice to the other parties of any change in address.

                                       13
<PAGE>

         8.7 Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the parties and their successors and assigns. Neither
the Company nor any Purchaser shall assign this Agreement or any rights or
obligations hereunder without the prior written consent of the other.

         8.8 Third Party Beneficiaries. This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and
assigns and is not for the benefit of, nor may any provision hereof be enforced
by, any other Person.

         8.9 Survival; Indemnification. The representations and warranties of
the Company and the agreements and covenants shall survive the Closing hereunder
notwithstanding any due diligence investigation conducted by or on behalf of
Purchaser. The Company agrees to indemnify and hold harmless each Purchaser and
each of each Purchaser's officers, directors, employees, partners, agents and
affiliates from and against any and all losses, claims, damages, liabilities and
expenses (including without limitation reasonable attorneys' fees and
disbursements and other expenses incurred in connection with investigating,
preparing or defending any action, claim or proceeding, pending or threatened
and the costs of enforcement thereof) (collectively, "Losses") arising as a
result of or related to any breach or alleged breach by the Company of any of
its representations or covenants set forth herein, including advancement of
expenses as they are incurred. The representations and warranties of the
Purchasers shall survive the Closing hereunder and each Purchaser shall
indemnify and hold harmless the Company and each of its officers, directors,
employees, partners, agents and affiliates from and against any and all Losses
arising as a result of the breach of such Purchaser's representations and
warranties.

         8.10 Further Assurances. Each party shall do and perform, or cause to
be done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

         8.11 Remedies. No provision of this Agreement providing for any remedy
to a Purchaser shall limit any remedy which would otherwise be available to such
Purchaser at law or in equity. Nothing in this Agreement shall limit any rights
a Purchaser may have with any applicable federal or state securities laws with
respect to the investment contemplated hereby. The Company acknowledges that a
breach by it of its obligations hereunder will cause irreparable harm to a
Purchaser. Accordingly, the Company acknowledges that the remedy at law for a
material breach of its obligations under this Agreement will be inadequate and
agrees, in the event of a breach or threatened breach by the Company of the
provisions of this Agreement, that a Purchaser shall be entitled, in addition to
all other available remedies, to an injunction restraining any breach and
requiring immediate compliance, without the necessity of showing economic loss
and without any bond or other security being required.

         8.12 Final Agreement. This Agreement, when executed by the parties
hereto, shall constitute the final agreement between the parties and upon such
execution Purchasers and the Company accept the terms hereof and have no cause
of action against each other for prior negotiations preceding the execution of
this Agreement.

                                       14
<PAGE>

         IN WITNESS WHEREOF, the undersigned Purchasers and the Company have
caused this Agreement to be duly executed as of the date first above written.

COMPANY:

BIOSTAR PHARMACEUTICALS, INC.

By:
         -----------------------------------------------------
         Name:
         Title:

PURCHASERS:

----------------------------------------             $----------------
Signature
                                                     Number of Units: __________
---------------------------------------
Name Typed or Printed

         Address: ______________________

                 Telephone: _____________

----------------------------------------             $----------------
Signature
                                                     Number of Units: __________
----------------------------------------
Name Typed or Printed

         Address: ______________________

                 Telephone: _____________

                                       15
<PAGE>

                                LIST OF EXHIBITS

EXHIBIT A         -        FORM OF WARRANT

EXHIBIT B         -        ACCREDITED INVESTOR QUESTIONNAIRE

                                       16
<PAGE>

                                    EXHIBIT A
                                       TO
                 PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT

                                 FORM OF WARRANT

                                       17
<PAGE>

                                    EXHIBIT B
                                       TO
                 PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT

                        ACCREDITED INVESTOR QUESTIONNAIRE

                                       18
<PAGE>

                                LIST OF SCHEDULES
                                       TO
                   COMMON STOCK AND WARRANT PURCHASE AGREEMENT

Schedule 1        -        List of Investors

Schedule 2        -        Company Disclosure Schedules

Schedule 3        -        Capitalization

                                       19
<PAGE>

<TABLE>
<CAPTION>

                                                  SCHEDULE 1
                               TO PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT

                                               LIST OF INVESTORS

---------------------------------------------- ------------------------------ ---------------------- -----------------------
Investor                                         Shares of Preferred Stock       Warrant Shares       Aggregate Purchase
--------                                         -------------------------       --------------       ------------------
<S>     <C>    <C>    <C>    <C>    <C>    <C>
Name and Address and Telephone Number                                                                        Price
-------------------------------------                                                                        -----
---------------------------------------------- ------------------------------ ---------------------- -----------------------
---------------------------------------------- ------------------------------ ---------------------- -----------------------

---------------------------------------------- ------------------------------ ---------------------- -----------------------
---------------------------------------------- ------------------------------ ---------------------- -----------------------

---------------------------------------------- ------------------------------ ---------------------- -----------------------
---------------------------------------------- ------------------------------ ---------------------- -----------------------

---------------------------------------------- ------------------------------ ---------------------- -----------------------
---------------------------------------------- ------------------------------ ---------------------- -----------------------

---------------------------------------------- ------------------------------ ---------------------- -----------------------
---------------------------------------------- ------------------------------ ---------------------- -----------------------

---------------------------------------------- ------------------------------ ---------------------- -----------------------
---------------------------------------------- ------------------------------ ---------------------- -----------------------

---------------------------------------------- ------------------------------ ---------------------- -----------------------
---------------------------------------------- ------------------------------ ---------------------- -----------------------

                  TOTALS:
---------------------------------------------- ------------------------------ ---------------------- -----------------------
</TABLE>

                                       20
<PAGE>

                                                  SCHEDULE 2
                                                      TO
                                PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT

                                         COMPANY DISCLOSURE SCHEDULES

                                       21
<PAGE>

                                                  SCHEDULE 3
                                                      TO
                                PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT

                                                CAPITALIZATION
                                                 AS OF , 2007

                                                             NUMBER OF SHARES
AUTHORIZED STOCK AS:
         Common Stock:                                       100,000,000
            Series A Preferred                                 5,000,000
             Blank Check Preferred Stock                       5,000,000
OUTSTANDING STOCK:
         Common Stock:                                                 0
            Series A Preferred                                         0
            Blank Check Preferred Stock                                0
STOCK OPTIONS:                                                         0

                                       22AMENDMENT

         THIS AMENDMENT (the "Amendment") is made and entered into as of
__________, 2007 by and between BIOSTAR PHARMACEUTICALS, INC., a Maryland
corporation (the "Company"), with headquarters located at Shiji Avenue, Xianyang
City, Shaanxi province, P.R. China, 712000, and_____________________ ( the
"Purchaser").

                                    RECITALS

         WHEREAS, the Company and the Purchaser entered into a Preferred Stock
and Warrant Purchase Agreement as of _________, 2007 pursuant to which the
Purchaser purchases shares of the Company's Series A Convertible Stock and the
Common Stock Purchase Warrants (the "Agreement"); and

         WHEREAS, the Company and the Purchaser wish to amend the Agreement as
set forth herein; and

         NOW, THEREFORE, in consideration of the foregoing premises, and the
mutual covenants and obligations set forth herein, the Company and the Purchaser
hereby agree as follows:

ARTICLE I

                                    AMENDMENT

         1. Amendment to Section 1.1 of the Agreement. The reference to "the
Company" in the eighth line of Section 1.1 of the Agreement shall be deleted and
"the Purchaser" shall be substituted therefor.

         2. Amendment to Section 4.2 of the Agreement. Section 4.2 of the
Agreement shall be deleted in its entirety and replaced with following:

               "Securities Laws; Disclosure; Press Release. The Company agrees
to file a Form D with respect to the Securities with the SEC as required under
Regulation D."

         3. Amendment to Section 4.6 of the Agreement. Section 4.6 of the
Agreement shall be deleted in its entirety and replaced with as the following:

         " 4.6 Conversion.

                 (i) Each share of Series A Preferred Stock is convertible into
shares of Common Stock at the Conversion Price (as such term hereinafter
defined) for such share, determined as hereafter provided, immediately upon the
valuation of the Common Stock by the Valuation Firm (as defined below) (the
"Conversion Trigger Date"). Prior to the initial filing of a registration
statement under the Securities Act of 1933, the corporation shall obtain from a

                                       1
<PAGE>

person, firm or entity engaged in the business of providing evaluations or
appraisals of the value of securities of companies which is selected in good
faith by the Board of Directors of the corporation and is independent of the
corporation (the "Valuation Firm") a valuation of the Common Stock on a per
share basis (the "Valuation Price"). For purposes hereof, the term "Conversion
Price" shall mean the price equal to the product obtained by multiplying (x)
1/3, times (y) 80% of the Valuation Price. The number of shares of Common Stock
issuable upon conversion of one share of Series A Preferred shall be the
quotient obtained by dividing (A) $10 by (B) the Conversion Price. The number of
Shares of Common Stock which may be issued upon converision of the Series A
Preferred shall be no more than 2 million shares. No fractional shares of Common
Stock may be issued upon the conversion of any share or shares of the Series A
Preferred Stock into Common Stock, and the number of shares of Common Stock to
be issued shall be rounded up to the nearest whole share. The Conversion Price
shall be appropriately adjusted in the event of a reorganization,
recapitalization, stock split, stock dividend, combination of shares, or similar
change in the corporation's Common Stock. In the event that no registration
statement is effective after the Conversion Trigger Date for the sale or re-sale
of the Common Stock issuable upon conversion, the corporation may deliver
restricted Common Stock upon conversion. Except as set forth herein, neither the
corporation nor any holder of Series A Preferred shall have the right to
convert, or require the conversion of, Series A Preferred into Common Stock or
any other security or property of the corporation or any other person.

              (ii) Mechanics of Conversion. Beginning on the Conversion Trigger
Date, any holder of the Series A Preferred may deliver or cause to be delivered
a notice to the corporation (A) stating that such holder wishes to convert the
Series A Preferred ; (B) setting forth the number of full shares of Common Stock
to be issued due to such conversion as determined in accordance with this
Section (4.6)(i); (C) surrendering the Series A Preferred certificate in
exchange for a Common Stock certificate representing the number of shares into
which such holder's Series A Preferred will be converted. The person entitled to
receive the shares of Common Stock issuable upon such conversion shall be
treated for all purposes as the record holder of such shares of Common Stock at
and after such time."

         4. Amendment to Form of Warrant. The Form of Warrant shall be restated
as in Exhibit A. Upon presentation and surrender of the original Warrant to the
Company, a new Warrant will be issued to the Holder within five (5) business
days.

                                   ARTICLE II

                                  MISCELLANEOUS

1. Amendments. The terms and provisions set forth in this Amendment shall modify
and supersede all inconsistent terms and provisions set forth in the Agreement.
The parties agree that the Agreement, as amended hereby, shall continue to be
legal, valid, binding and enforceable in accordance with its terms.

                                       2
<PAGE>

         2. Survival of Representations and Warranties. All express, written
representations and warranties contained in the Agreement shall survive the
execution and delivery of this Amendment.

         3. Headings. The section headings contained in this Amendment are for
purposes of convenience only, and shall in no way bear upon the construction or
interpretation of this Amendment.

         4. Entire Agreement. This Agreement contains the entire agreement
between the Company and the Purchaser and shall be binding upon and inure to the
benefit of each party. Except as set forth in the Agreement, as amended hereby,
no representations, warranties or promises have been made or relied upon by the
Company or the Purchaser in entering into the Agreement or this Amendment. The
Agreement, as amended hereby, shall prevail over prior communications between
the Company and the Purchaser or their representatives regarding the matters
contained herein.

         5. Modification and Waiver. This Amendment may not be modified or
amended except by an instrument or instruments in writing signed by the parties
hereto. No waiver of any of the provisions of this Amendment shall be deemed, or
shall constitute, a waiver of any other provisions, whether or not similar. No
waiver shall be binding unless executed in writing by the party making the
waiver.

         6. Counterparts. This Amendment may be executed simultaneously in one
or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.

         7. Severability. The provisions of this Amendment are severable, and
the invalidity of any provision shall not affect the validity of any other
provisions.

         8. Binding Effect. This Amendment shall be binding upon, and shall
inure to the benefit of the parties hereto and their respective successors and
permitted
assigns.

         9. Governing Law. This Amendment, its validity, interpretation and
performance shall be governed by and construed in accordance with the internal
laws of the State of New York without giving effect to the conflict of laws
provisions thereof.

                                       3
<PAGE>

         IN WITNESS WHEREOF, this Amendment has been executed and is effective
as of the date hereof.

COMPANY:

BIOSTAR PHARMACEUTICALS, INC.

By:
         -----------------------------------------------------
         Name:    Ronghua Wang
         Title:   President

PURCHASERS:

By:
         -----------------------------------------------------
         Name:
         Title:

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]